Why Is CNS Pharmaceuticals Stock (CNSP) Up Today?

CNS Pharmaceuticals (CNSP) stock rocketed higher on Monday after the pharmaceutical company announced an oversubscribed $22.5 million private placement. Institutional healthcare investors, including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management, and Nazare Partners, took part in this private placement.

Under the terms of this private placement, CNS Pharmaceuticals has agreed to sell 650,000 shares of CNSP for $2.30 each. The private placement also included pre-funded warrants for another 9,143,479 shares being sold for $2.299 each, with an exercise price of $0.001 per share. The offering is set to close on Tuesday.

Rami Levin, president and CEO of CNS Pharmaceuticals, said, “With the proceeds from this financing, the Company is now in a strong position to execute on our recently announced corporate strategy and capitalize on opportunities created by the dynamic biotech environment over the last several years. We expect that the proceeds from the private placement will help us acquire assets with clear development pathways with identifiable near-term catalysts, and with the potential to deliver meaningful value to patients and shareholders.”

CNS Pharmaceuticals Stock Movement Today

CNS Pharmaceuticals stock was up 215.39% on Monday, extending an 89.52% rally year-to-date. Despite these gains, the stock was still down 82.49% over the past 12 months.

With today’s news came heavy trading of CNSP stock, as more than 44 million shares changed hands. For comparison, the company’s three-month average daily trading volume is about 16,000 shares.

Is CNS Pharmaceuticals Stock a Buy, Sell, or Hold?

Turning to Wall Street, only one analyst has covered CNS Pharmaceuticals stock over the past three months. Maxim Group analyst Jason McCarthy holds a Buy rating and a $10 price target for CNSP stock, representing a potential 5.6% upside for the shares.